Prodotti competitors / Area Oncology
FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
On August 2, 2023, the Food and Drug Administration (FDA) approved trifluridine and tipiracil (Lonsurf Taiho Oncology, Inc.) with bevacizumab, for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
FDA had previously approved single-agent Lonsurf for this indication in September 2015.
Grazie per il tuo feedback!